Research Library
Research, by compound.
Evidence-based, research-use overviews of peptides and compounds — grouped by compound. Tap a compound to open its research. For laboratory and educational reference only.
BPC-157 Research FAQ
Common questions about BPC-157 answered in a research context — what it is, what studies examine, and the limits of the evidence.
BPC-157 vs TB-500: What the Research Compares
Two peptides frequently studied in tissue-repair research — how BPC-157 and TB-500 differ in origin, structure, and the pathways the literature examines.
BPC-157: Mechanism of Action in Published Studies
A research-framed look at the specific signaling pathways published studies have associated with BPC-157 in laboratory models.
BPC-157 Peptide: A Complete Research Overview
An evidence-based research overview of BPC-157 — what the peptide is, the mechanisms studied in preclinical models, key published studies, and its research-use status.
Epithalon Research FAQ
Frequently asked questions about Epithalon (Epitalon, AEDG) answered strictly in a research context — what the published literature has studied, what it has not, and what the evidence actually supports.
Epithalon, the Pineal Gland & Circadian Signaling in Research
A research-framed look at what published studies have examined regarding Epithalon's relationship to pineal gland melatonin output and circadian clock-gene signaling — what the animal and small human-subject data reported, and what it does not tell us.
Epithalon & Telomerase Activity in Published Research
A research-framed look at the laboratory studies that have examined Epithalon's relationship to telomerase activity and telomere biology — what the cell-culture data actually reported and what it cannot tell us about human outcomes.
Epithalon Peptide: A Research Overview
An evidence-based research overview of Epithalon (Epitalon, the AEDG peptide) — what the peptide is, the mechanisms studied in preclinical and in-vitro models, key published studies, and its research-use status.
GHK-Cu Research FAQ
Common questions about GHK-Cu, answered strictly in a research context — what studies have examined, how the literature is characterized, and what is and is not established.
GHK-Cu vs Other Skin Peptides: What the Research Compares
A research-framed comparison of how GHK-Cu differs from palmitoyl peptides, matrikine sequences, and other compounds studied in dermatological and ECM biology research — based on what the published literature actually examines.
GHK-Cu: Mechanism in Published Studies
A research-framed look at the specific signaling pathways published studies have associated with GHK-Cu in laboratory models — ECM remodeling, MMP/TIMP regulation, collagen synthesis, and gene-expression observations.
GHK-Cu Copper Peptide: A Research Overview
An evidence-based research overview of GHK-Cu (copper tripeptide-1) — what the peptide is, the mechanisms studied in preclinical and in-vitro models, key published studies, and its research-use status.
Semax Research FAQ: Common Questions Answered in a Research Context
Common questions about Semax — the synthetic ACTH-derived heptapeptide — answered strictly in a research context, with citations from the published pre-clinical literature.
Semax vs. Selank: What the Published Research Compares
A research-framed comparison of two synthetic heptapeptides developed in Russian neuroscience programs — Semax and Selank — examining how the published pre-clinical literature characterizes their differing structural origins and studied signaling pathways.
Semax, BDNF & Melanocortin Signaling in Published Research
A research-framed look at the specific neurotrophin and receptor signaling pathways published studies have associated with the synthetic heptapeptide Semax in laboratory models.
Semax Peptide: A Research Overview
An evidence-based research overview of Semax, a synthetic ACTH(4-10) analog peptide — what it is, the mechanisms studied in preclinical and in-vitro models, key published studies, and its research-use status.
CJC-1295 Research FAQ: Common Questions Answered in a Research Context
Common questions about CJC-1295 answered in a research register — what the compound is, how published studies have characterized it, how it relates to other GHRH analogs, and what researchers should know about the literature.
CJC-1295 vs. Sermorelin vs. Tesamorelin: What the Research Compares
A research-framed comparison of three synthetic GHRH-based peptide analogs — CJC-1295, Sermorelin, and Tesamorelin — examining how published literature characterizes their structural differences, receptor pharmacology, and the distinct research contexts in which each has been studied.
CJC-1295, the GHRH Receptor & Half-Life in Published Research
A research-framed look at the specific molecular modifications that define CJC-1295 as a GHRH-receptor agonist, and what published pharmacokinetic studies have observed about its plasma half-life relative to native GHRH.
Glutathione Research FAQ: Common Questions Answered in a Research Context
Frequently asked questions about Glutathione (GSH) — answered strictly in the context of published biochemistry and pre-clinical research, not as health guidance.
Glutathione vs. Its Precursors: What the Research Literature Compares
A research-framed look at how published studies distinguish direct glutathione (GSH) from biosynthetic precursors — particularly N-acetylcysteine (NAC) and cysteine — in terms of cellular handling, bioavailability in experimental models, and the biochemical pathways each engages.
Glutathione, Redox Balance & Oxidative Stress in Published Research
A research-framed look at what published biochemistry has characterized about the GSH/GSSG redox cycle, glutathione peroxidase, and glutathione reductase in cell-based and enzymatic studies.
Ipamorelin Research FAQ
Common questions about Ipamorelin answered in a research context — what the published literature has studied, how it differs from other GH-releasing peptides, and what the evidence base actually says.
Ipamorelin vs. Other GH-Releasing Peptides: What the Research Compares
How published research characterizes Ipamorelin relative to other GH-releasing peptides (GHRP-2, GHRP-6, Hexarelin) — selectivity, metabolite profiles, and receptor pharmacology as studied in laboratory models.
Ipamorelin and the Ghrelin/GHSR-1a Receptor in Published Research
A research-framed look at what published studies have examined regarding Ipamorelin's interaction with the ghrelin/GHSR-1a receptor — how the receptor works, what selectivity means in a laboratory context, and what the pre-clinical literature observes.
NAD+ Research FAQ: Common Questions Answered in a Research Context
Frequently asked questions about NAD+ research — what studies have examined, how precursors NMN and NR relate, and how to understand the current state of the literature.
NAD+ vs NMN vs NR: What the Precursor Research Compares
A research-framed comparison of NAD+ and its precursors nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — how the three forms differ structurally, how the literature characterizes their pharmacokinetics, and what early human studies have examined.
NAD+, Sirtuins & Mitochondrial Function in Published Research
A research-framed look at what published studies have examined about the NAD+–sirtuin axis and its relationship to mitochondrial dynamics in laboratory and animal models.
PT-141 Research FAQ: Common Questions, Research-Register Answers
Common questions about PT-141 (bremelanotide) answered strictly in a research context — receptor pharmacology, compound structure, literature status, and what published studies have and have not examined.
PT-141 vs Other Melanocortin-System Peptides: What the Research Compares
A research-framed comparison of how published studies characterize PT-141 (bremelanotide) relative to other melanocortin-system peptides — including α-MSH, melanotan II, and setmelanotide — at the receptor and structural levels.
PT-141 and the Melanocortin Receptors (MC4R/MC3R) in Published Research
A research-framed look at the specific melanocortin receptor subtypes — MC4R and MC3R — that published studies have associated with PT-141 (bremelanotide) in laboratory and pre-clinical models.
Tesamorelin Research FAQ
Common questions about Tesamorelin answered in a research context — what it is, how published studies have characterized its pharmacology, how it compares to related GHRH analogs, and what the literature does and does not support.
Tesamorelin vs CJC-1295 vs Sermorelin: A Research-Framed Comparison of GHRH Analogs
How published research characterizes the structural, pharmacokinetic, and regulatory differences among three synthetic analogs of growth-hormone-releasing hormone — Tesamorelin, CJC-1295, and Sermorelin — and what those differences mean in a laboratory context.
Tesamorelin, the GHRH Receptor & IGF-1 Axis in Published Research
A research-framed look at how published studies characterize Tesamorelin's interaction with the pituitary GHRH receptor and the downstream IGF-1 axis — what the signaling cascade looks like in the laboratory literature.
